Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Surg Oncol. 2014 Feb 27;12:46. doi: 10.1186/1477-7819-12-46.

Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).

Author information

  • 1Medical Oncology 1 Unit, ISTITUTO ONCOLOGICO VENETO IOV- IRCCS, Via Gattamelata 64, 35128 Padova, Italy. umberto.basso@ioveneto.it.

Abstract

Perivascular epithelioid cell tumors (PEComas) are rare soft-tissue tumors with an extremely heterogeneous clinical behavior. They may arise in different organs and may behave indolently or sometimes metastasize with different grades of biological aggressiveness. We report the case of a young woman with a primary inoperable PEComa of the liver with malignant histological features. Since the mTOR pathway is often altered in PEComas and responses have been reported with mTOR-inhibitors such as sirolimus or temsirolimus, we decided to start a neoadjuvant treatment with sirolimus. The patient tolerated the treatment fairly well and after 8 months a favorable tumor shrinkage was obtained. The patient then stopped sirolimus and 2 weeks later underwent partial liver resection, with complete clinical recovery and normal liver function. The histological report confirmed a malignant PEComa with vascular invasion and negative margins. Then 6 additional months of post-operative sirolimus treatment were administered, followed by regular radiological follow-up. For patients with a large and histologically aggressive PEComa, we think that neoadjuvant treatment with mTOR-inhibitor sirolimus may be considered to facilitate surgery and allow early control of a potentially metastatic disease. For selected high-risk patients, the option of adjuvant treatment may be discussed.

PMID:
24575738
PMCID:
PMC3943801
DOI:
10.1186/1477-7819-12-46
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center